Insilico Medicine
Insilico Medicine to Present Three Abstracts on ISM5411 at 2026 Crohn’s & Colitis Congress
Insilico Medicine; ISM5411; Crohn’s & Colitis Congress; Inflammatory Bowel Disease; PHD1/2 Inhibitor; Phase 1 Data
Insilico Medicine Integrates Nach01 Foundation Model with Microsoft Discovery for AI-Native Drug Discovery
Insilico Medicine; Nach01; Microsoft Discovery; AI drug discovery; Azure; foundation model
Insilico Medicine and Servier Announce Up to $888 Million AI-Driven Oncology R&D Collaboration
Insilico Medicine; Servier; AI platform; oncology; drug discovery; Pharma.AI; $888 million
Insilico Medicine Caps 2025 with Record HKD 2.277 Billion Hong Kong IPO
Insilico Medicine; Hong Kong IPO; AI biotech; HKEX listing; drug discovery
Models are out, molecules are in as AI drug startups sprint to the clinic
AI drug discovery; AI-designed molecules; clinical-stage AI startups; small-molecule therapeutics; biotech funding; Insilico Medicine; Recursion Pharmaceuticals; Absci; PsiThera; clinical trials
Insilico Medicine and TaiGen sign exclusive licensing deal for AI-designed PHD inhibitor ISM4808 to treat anemia in chronic kidney disease
Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech
Insilico Medicine and Menarini Group’s Stemline Therapeutics Announce Second Exclusive Licensing Agreement for AI-Discovered Oncology Drug Candidate
Insilico Medicine, Menarini Group, Stemline Therapeutics, AI-generated cancer drug, Oncology drug candidate, Licensing agreement, $550 million deal